Edition:
United States

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

14.50USD
3:59pm EST
Change (% chg)

$0.08 (+0.52%)
Prev Close
$14.43
Open
$14.45
Day's High
$14.90
Day's Low
$14.35
Volume
119,372
Avg. Vol
219,473
52-wk High
$36.80
52-wk Low
$11.93

Chart for

About

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $509.03
Shares Outstanding(Mil.): 35.29
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.83 15.71
EPS (TTM): -- -- --
ROI: -- 15.03 31.93
ROE: -- 16.54 16.16

BRIEF-Amag Pharmaceuticals Q3 loss per share $4.31

* Amag Pharmaceuticals announces third quarter 2017 financial results and business highlights

Nov 02 2017

BRIEF-Amag Pharmaceuticals announces U.S. FDA filing acceptance

* Amag announces U.S. FDA filing acceptance and six-month review of Feraheme® (Ferumoxytol) for the treatment of all adult patients with iron deficiency anemia

Aug 31 2017

BRIEF-Amag Pharmaceuticals Q2 loss per share $0.40

* Amag pharmaceuticals announces second quarter 2017 financial results and provides corporate update

Aug 03 2017

BRIEF-Amag completes feraheme FDA submission for the treatment of all adult patients with iron deficiency anemia

* Amag completes Feraheme® (ferumoxytol) FDA submission for the treatment of all adult patients with iron deficiency anemia

Aug 03 2017

BRIEF-Amag Pharmaceuticals announces commercial availability of Intrarosa (prasterone) at U.S. pharmacies

* Says announces commercial availability of intrarosa (prasterone) at U.S. pharmacies

Jul 24 2017

BRIEF-Amag reports U.S. FDA acceptance of supplemental new drug application for Makena

* Amag announces U.S. FDA filing acceptance of supplemental new drug application for makena® (hydroxyprogesterone caproate injection) subcutaneous auto-injector

Jun 26 2017

Earnings vs. Estimates